Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Reports Strong Q2 2026 Financial Results and Revises Guidance
Summary
Alnylam Pharmaceuticals, Inc. reported a 74% increase in total net product revenues for Q2 2026, reaching $1.17 billion, driven by strong performance in its TTR franchise. The company revised its full-year 2026 TTR net product revenue guidance from $4.4-4.7 billion to $4.2-4.5 billion, reflecting normalized growth in the ATTR-CM market. Alnylam also highlighted progress in its clinical trials and strategic collaborations. The company's financial results exceeded expectations, and the guidance revision was due to market learnings.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement